Biotech Company Presents Promising Data For Acute Myeloid Leukemia Treatment
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting.
Disclaimer: This article is for informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Readers are advised to consult with healthcare professionals for any medical concerns.